Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin.

Abstract

A total of 54 women with acute salpingitis were treated intravenously with ampicillin/sulbactam or cefoxitin in a prospective, randomized, ongoing study. Of the organisms isolated, Gram-negative species (excluding Neisseria gonorrhoeae) were considerably more likely to produce beta-lactamase than were Gram-positive species. Clinical efficacy was 94% for 2 g ampicillin plus 1 g sulbactam and 89% for 2 g cefoxitin, all given intravenously every 6 h. The addition of sulbactam, an irreversible beta-lactamase inhibitor, to ampicillin restored both the microbiological and clinical activities of ampicillin. Both regimens were equally safe and demonstrated good efficacy in the treatment of the acute, symptomatic phase of infection.

• Authors: D L Hemsell, R E Bawdon, P G Hemsell, B J Nobles, M C Heard
• Journal: The Journal of international medical research (J Int Med Res) Vol. 18 Suppl 4 Pg. 85D-89D ( 1990) ISSN: 0300-0605 [Print] England
• PMID: 2282973 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• beta-Lactamase Inhibitors
• Cefoxitin
• Ampicillin
• beta-Lactamases
• Sulbactam

Topics

• Acute Disease
• Adult
• Ampicillin (administration & dosage, therapeutic use)
• Cefoxitin (administration & dosage, therapeutic use)
• Drug Therapy, Combination (administration & dosage, therapeutic use)
• Female
• Humans
• Injections, Intravenous
• Pelvic Inflammatory Disease (drug therapy)
• Prospective Studies
• Remission Induction
• Sulbactam (administration & dosage, therapeutic use)
• beta-Lactamase Inhibitors
• beta-Lactamases (biosynthesis)